Fierce Pharma June 2, 2024
Almost 10 years ago, Merck ushered superstar cancer drug Keytruda across the FDA finish line for the first time, opening the door to dozens of additional indications over the years.
It was a “once-in-a-lifetime, lighting-in-a-bottle” discovery that wouldn’t be possible to develop the same way under the Inflation Reduction Act (IRA), Merck CEO Robert Davis warned at a Pharmaceutical Research and Manufacturers of America (PhRMA) panel Friday on the sidelines of this year’s annual American Society of Clinical Oncology (ASCO) conference.
While Davis says the drug and its development on its own is “not a repeatable model,” Eli Lilly’s CEO David Ricks argues that lighting could still strike twice—if it weren’t for the IRA.
Specifically, Ricks referred to the...
Today's Sponsors
Today's Sponsor